Being able to predict which cancer patient is likely to respond to chemotherapy with cisplatin has not yet been possible. However, a unique research project between NRG|PALLAS, the Netherlands Cancer Institute (NKI) and Amsterdam UMC may bring about some change.
Producing medical isotopes using only low enriched uranium? After a challenging design process, Curium and NRG are the first in Europe to produce molybdenum-99 with low enriched uranium. Recognizing the commitments made during the Nuclear Summit 2014, to phase out high enriched uranium (HEU) based medical isotopes.
A complex project has been brought to a successful conclusion: the development and installation of a production process for xenon-133 gas.
Recently, we have developed the world’s first fully automated synthesis module, for the synthesis of Pt-195m cisplatin and other platinum compounds
FIELD-LAB is a partnership that aims to convert knowledge into new medical solutions. The aim is to accelerate the process from development to the production of nuclear therapies for cancer patients.
NRG Advancing Nuclear Medicine cares for the well-being of people worldwide. Especially for their health. We wish people to live longer, be more vital and feel happier. We believe everybody should have access to advanced treatments. New highly targeted treatments will cause less side effects and improve the quality of life.
We provide solutions to advance nuclear medicine ranging from complete irradiation services for medical isotope production, to access to R&D resources & commercial processing.
The new FIELD-LAB establishment, dedicated to the production of medical isotopes for cancer treatment and which opened in December 2023, will operate under GMP standards. According to Harry Hendrikse, a professor Translational Radiopharmacology at Erasmus Medical Center and one of the GMP consultants who initially worked on this project, that is not an easy task.
Erasmus Medical Center in Rotterdam and NRG PALLAS teamed up last years within FIELD-LAB to realise a study on the stability and efficacy of different ligands in combination with Lead-212 for the treatment of NETs. And the results were promising.